Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Neuroscience ; 358: 227-237, 2017 09 01.
Artigo em Inglês | MEDLINE | ID: mdl-28687315

RESUMO

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the progressive loss of memory. The neurodegeneration induced by AD has been linked to oxidative damage. However, little is known about the involvement of NADPH oxidase 2 (Nox2), a multisubunit enzyme that catalyzes the reduction of oxygen to produce reactive oxygen species, in the pathogenesis of AD. The main purpose of this study was to investigate the involvement of Nox2 in memory, in AD-related brain abnormalities, oxidative damage, inflammation and neuronal death in the hippocampus in the streptozotocin (STZ)-induced AD-like state by comparing the effects of that drug on mice lacking gp91phox-/- and wild-type (Wt) mice. Nox2 gene expression was found increased in Wt mice after STZ injection. In object recognition test, Wt mice injected with STZ presented impairment in short- and long-term memory, which was not observed following Nox2 deletion. STZ treatment induced increased phosphorylation of Tau and increased amyloid-ß, apoptosis-inducing factor (AIF) and astrocyte and microglial markers expression in Wt mice but not in gp91phox-/-. STZ treatment increased oxidative damage and pro-inflammatory cytokines' release in Wt mice, which was not observed in gp91phox-/- mice. Nox2 deletion had a positive effect on the IL-10 baseline production, suggesting that this cytokine might contribute to the neuroprotection mechanism against STZ-induced neurodegeneration. In summary, our data suggest that the Nox2-dependent reactive oxygen species (ROS) generation contributes to the STZ-induced AD-like state.


Assuntos
NADPH Oxidase 2/metabolismo , Aldeídos/metabolismo , Peptídeos beta-Amiloides/metabolismo , Animais , Antibióticos Antineoplásicos/toxicidade , Fator de Indução de Apoptose/metabolismo , Antígeno CD11b/metabolismo , Citocinas/metabolismo , Modelos Animais de Doenças , Proteína Glial Fibrilar Ácida/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos C57BL , NADPH Oxidase 2/genética , Doenças Neurodegenerativas/induzido quimicamente , RNA Mensageiro/metabolismo , Receptores Imunológicos/deficiência , Receptores Imunológicos/genética , Reconhecimento Psicológico/fisiologia , Estreptozocina/toxicidade , Proteínas tau/metabolismo
2.
Neurotox Res ; 31(3): 327-333, 2017 04.
Artigo em Inglês | MEDLINE | ID: mdl-27913964

RESUMO

Streptozotocin has been widely used to mimic some aspects of Alzheimer's disease (AD). However, especially in mice, several characteristics involved in the streptozotocin (STZ)-induced AD pathology are not well known. The main purpose of this study was to evaluate temporally the expression of AD-related proteins, such as amyloid-ß (Aß), choline acetyltransferase (ChAT), synapsin, axonal neurofilaments, and phosphorylated Tau in the hippocampus following intracerebroventricular (icv) administration of STZ in adult mice. We also analyzed the impact of STZ on short- and long-term memory by novel object recognition test. Male mice were injected with STZ or citrate buffer, and AD-related proteins were evaluated by immunoblotting assays in the hippocampus at 7, 14, or 21 days after injection. No differences between the groups were found at 7 days. The majority of AD markers evaluated were found altered at 14 days, i.e., the STZ group showed increased amyloid-ß protein and neurofilament expression, increased phosphorylation of Tau protein, and decreased synapsin expression levels compared to controls. Except for synapsin, all of these neurochemical changes were transient and did not last up to 21 days of STZ injection. Moreover, both short-term and long-term memory deficits were demonstrated after STZ treatment at 14 and 21 days after STZ treatment.


Assuntos
Peptídeos beta-Amiloides/metabolismo , Colina O-Acetiltransferase/metabolismo , Hipocampo/metabolismo , Filamentos Intermediários/metabolismo , Transtornos da Memória/induzido quimicamente , Estreptozocina , Sinapsinas/metabolismo , Proteínas tau/metabolismo , Doença de Alzheimer/induzido quimicamente , Doença de Alzheimer/metabolismo , Doença de Alzheimer/psicologia , Animais , Modelos Animais de Doenças , Infusões Intraventriculares , Masculino , Camundongos , Fosforilação , Reconhecimento Psicológico/efeitos dos fármacos , Estreptozocina/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA